<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29598" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Subacute Bacterial Endocarditis Prophylaxis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ibrahim</surname>
            <given-names>Abdisamad M.</given-names>
          </name>
          <aff>Southern Illinois Un School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Siddique</surname>
            <given-names>Momin S.</given-names>
          </name>
          <aff>SIU</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdisamad Ibrahim declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Momin Siddique declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29598.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Infective endocarditis is an infection of the heart's endocardial surfaces involving one or more heart valves. The incidence of infective endocarditis hospitalization rate is estimated at 12.7 per 100,000 annually in the United States. Most patients (57.7%) affected by this condition were male, and over one-third were aged 70 or older. Several risk factors can predispose patients to infective endocarditis, including structural heart disease (such as valvular disease or congenital heart disease), prosthetic heart valves, indwelling cardiovascular device, intravascular catheter, chronic hemodialysis, HIV infection, diabetes, or a prior history of infective endocarditis.</p>
        <p>Infective endocarditis can manifest as either acute or subacute infection. Acute infections are characterized by rapid progression, marked by high fevers, rigors, and sepsis.&#x000a0;Conversely, the diagnosis of subacute bacterial endocarditis is often delayed and is characterized by nonspecific symptoms such as weight loss, fatigue, and dyspnea over a period of weeks to months. Clear distinctions exist between subacute and acute bacterial endocarditis. Penicillin-sensitive <italic toggle="yes">Streptococcus&#x000a0;viridans</italic>&#x000a0;is the predominant cause of most cases of subacute bacterial endocarditis, whereas <italic toggle="yes">Staphylococcus aureus</italic> is responsible for the majority of acute bacterial endocarditis cases. Managing both types of bacteria necessitates distinct prophylactic approaches to prevent further complications of infective endocarditis. This activity reviews the prophylaxis of subacute infective endocarditis and highlights the crucial role of the interprofessional healthcare team in managing this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients at risk for subacute bacterial endocarditis based on clinical history, underlying cardiac conditions, and predisposing factors.</p></list-item><list-item><p>Implement appropriate antibiotic prophylaxis strategies in accordance with current guidelines and evidence-based recommendations for subacute bacterial endocarditis.</p></list-item><list-item><p>Select optimal antibiotic regimens for prophylaxis based on patient-specific factors, including allergies, comorbidities, and procedural risks, for treating subacute bacterial endocarditis.</p></list-item><list-item><p>Collaborate with interprofessional team members, including cardiologists and infectious disease specialists, to ensure comprehensive management of patients at risk for subacute bacterial endocarditis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29598&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29598">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29598.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Infective endocarditis is an infection of the heart's endocardial surfaces involving one or more heart valves. The incidence of infective endocarditis hospitalization rate is estimated at 12.7 per 100,000 annually&#x000a0;in the United States. Most patients (57.7%) affected by this condition were male, and over one-third were aged 70 or older.<xref ref-type="bibr" rid="article-29598.r1">[1]</xref>&#x000a0;</p>
        <p>Several risk factors can predispose patients to infective endocarditis,&#x000a0;including&#x000a0;structural heart disease (such as valvular disease or congenital heart disease), prosthetic heart valves, indwelling cardiovascular device, intravascular catheter, chronic hemodialysis,&#x000a0;HIV&#x000a0;infection, diabetes, or a prior history of infective endocarditis. Additional risk factors include male gender, males aged 60 or older, intravenous (IV) drug use, poor dentition, or dental infection.</p>
        <p>Infective endocarditis can manifest as either acute or subacute infection.<xref ref-type="bibr" rid="article-29598.r2">[2]</xref>&#x000a0;Acute infections are characterized by rapid progression, marked by high fevers, rigors, and sepsis.&#x000a0;Conversely, the diagnosis of subacute bacterial endocarditis is often delayed and is characterized by nonspecific symptoms such as weight loss, fatigue, and dyspnea over a period of weeks to months. Clear distinctions exist between subacute and acute bacterial endocarditis. Penicillin-sensitive&#x000a0;<italic toggle="yes">Streptococcus&#x000a0;viridans</italic>&#x000a0;is the predominant cause of most cases of subacute bacterial endocarditis, whereas&#x000a0;<italic toggle="yes">Staphylococcus aureus</italic>&#x000a0;is responsible for the majority of acute bacterial endocarditis cases.<xref ref-type="bibr" rid="article-29598.r3">[3]</xref>&#x000a0;Managing both types of bacteria necessitates distinct prophylactic approaches to prevent further complications of infective endocarditis.</p>
        <p>Subacute bacterial endocarditis primarily arises in individuals with preexisting heart disease, whereas acute bacterial endocarditis predominantly affects those with healthy hearts. Following treatment, subacute bacterial endocarditis seldom results in significant cardiac damage; however, a considerable number of patients who survive acute bacterial endocarditis ultimately succumb to cardiac failure.<xref ref-type="bibr" rid="article-29598.r3">[3]</xref></p>
        <p>With the ongoing increase in the incidence of infective endocarditis in the United States, healthcare professionals face the imperative task of making judicious decisions regarding antibiotic prophylaxis to mitigate further complications. Historically, antibiotic prophylaxis before procedures, especially dental procedures, was used&#x000a0;extensively to prevent&#x000a0;infective endocarditis despite insufficient evidence supporting its efficacy. However, guidelines issued by the American Heart Association (AHA) in 2007 notably curtailed the indications for antibiotic use in endocarditis prophylaxis.<xref ref-type="bibr" rid="article-29598.r4">[4]</xref>&#x000a0;Several reasons were elucidated for this change. First, it was observed that infective endocarditis was more likely to develop from routine activities such as teeth brushing and flossing rather than a single medical or dental procedure. Second, the prevailing sentiment was that antibiotic prophylaxis for dental procedures offered minimal prevention against infective endocarditis cases. The expense of antibiotics, the potential for adverse effects, and the risk of fostering antibiotic resistance significantly outweighed the benefit of such preventive measures. Third, emphasis was placed on maintaining good oral hygiene, which provides greater efficacy in preventing infective endocarditis than a single dose of antibiotics.<xref ref-type="bibr" rid="article-29598.r4">[4]</xref></p>
        <p>Preventive measures against infective endocarditis include the following steps:</p>
        <list list-type="bullet">
          <list-item>
            <p>Maintaining optimal oral hygiene.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Administering antibiotics prophylactically before certain invasive dental or oral procedures.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Diagnosing and treating endocarditis infections promptly.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Utilizing antibiotic prophylaxis for surgical site infections to mitigate the risk of subsequent endocarditis. For instance, administering antibiotic prophylaxis before cardiac surgery serves as one example.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29598.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The rationale for taking prophylactic antibiotic therapy for subacute bacterial endocarditis includes the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Due to the fatal nature of infective endocarditis, prevention is preferable to treating established infections.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Specific cardiac conditions predispose individuals to infective endocarditis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Prophylactic antibiotics aim to decrease the incidence of bacteremia associated with invasive dental, oral, gastrointestinal, and genitourinary tract procedures.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Animal studies provide evidence supporting the efficacy of antimicrobial prophylaxis in preventing infective endocarditis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In humans, antimicrobial prophylaxis is effective in preventing infective endocarditis during high-risk dental, oral, gastrointestinal, or genitourinary tract procedures.<xref ref-type="bibr" rid="article-29598.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>Infective endocarditis&#x000a0;carries a fatal outcome if untreated or unrecognized. Despite advancements in antimicrobial therapy and surgical interventions, the condition continues to impose substantial morbidity and mortality. Consequently, preventive measures against infective endocarditis are imperative. Although animal studies suggest that antibiotic prophylaxis may be effective in preventing infective endocarditis, data from human studies remain insufficient. Thus, current guidelines in the United States advocate for antimicrobial prophylaxis in patients undergoing specific procedures at risk of infective endocarditis.</p>
        <p>The&#x000a0;AHA currently&#x000a0;recommends antibiotic prophylaxis for the following patients with&#x000a0;certain high-risk cardiac conditions:<xref ref-type="bibr" rid="article-29598.r6">[6]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Patients with prosthetic cardiac valves.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients with a prior history of infective endocarditis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients who have undergone cardiac transplantation and have valve regurgitation caused&#x000a0;by a&#x000a0;structurally abnormal valve.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients with congenital heart disease with:
<list list-type="bullet"><list-item><p>Unrepaired cyanotic congenital heart disease, including palliative shunts and conduits.</p></list-item><list-item><p>Repaired congenital heart defects, specifically those corrected with prosthetic material or devices placed during surgery or catheter intervention within the first 6 months following the procedure.</p></list-item><list-item><p>Repaired congenital heart disease with residual defects present at the site or adjacent to the site of a prosthetic patch or device.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Patients with these high-risk conditions should receive antibiotics for the following procedures:</p>
        <list list-type="bullet">
          <list-item>
            <p>Dental procedures,&#x000a0;including routine dental cleaning, drainage of dental abscesses, tooth extraction, manipulation of gingival tissue, manipulation of the periapical region of teeth, or perforation of the oral mucosa. However, routine anesthetic injections through noninfected tissue, dental radiographs, placement or adjustment of orthodontic devices, or trauma to the lips and teeth do not require antibiotic prophylaxis.<xref ref-type="bibr" rid="article-29598.r4">[4]</xref><xref ref-type="bibr" rid="article-29598.r7">[7]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Invasive respiratory tract procedures, as recommended by the 2007 AHA guidelines, include incision or biopsy of the respiratory mucosa, such as tonsillectomy and adenoidectomy. Antibiotic prophylaxis is unnecessary for bronchoscopy unless the procedure involves an incision of the respiratory tract mucosa.<xref ref-type="bibr" rid="article-29598.r4">[4]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Procedures involving infected skin, skin structures, or musculoskeletal tissue.<xref ref-type="bibr" rid="article-29598.r4">[4]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29598.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Antibiotics for&#x000a0;Infective Endocarditis</bold>
</p>
        <p>The most common bacteria to cause infective endocarditis for dental and respiratory procedures are the various species of&#x000a0;<italic toggle="yes">S viridans</italic>. The recommended prophylactic antibiotic is amoxicillin, administered orally 1 hour before the procedure. In cases where IV medications are necessary, ampicillin or ceftriaxone may be used. For patients with a penicillin allergy, cephalexin or azithromycin can be considered.&#x000a0;Notably,&#x000a0;some strains of <italic toggle="yes">S viridans</italic> exhibit penicillin resistance, prompting the prescribing clinician to consider local resistance patterns when selecting the appropriate antibiotic. Antistaphylococcal&#x000a0;penicillin or vancomycin is recommended when <italic toggle="yes">S aureus</italic> is suspected.<xref ref-type="bibr" rid="article-29598.r8">[8]</xref>&#x000a0;</p>
        <p>
<bold>Antibiotics Dosage</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Amoxicillin should be administered at a dose of 2 g for adults and 50 mg/kg for pediatric patients, with the pediatric dose not exceeding the adult dose.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cephalexin should be administered at a dose of 2&#x000a0;g for adults and 50 mg/kg for pediatric patients, with the pediatric dose not exceeding the adult dose.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Azithromycin/clarithromycin should be administered at a dose of 500 mg&#x000a0;for adults and 15 mg/kg for pediatric patients, with the pediatric dose not exceeding the adult dose.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Doxycycline should be administered at a dose of 100 mg for adults. For pediatric patients with a body weight of 45 kg or less, the doxycycline dose is 2.2 mg/kg, whereas for those with a body weight of more than 45 kg, the doxycycline&#x000a0;dose is 100 mg.&#x000a0;However, the pediatric dose should not exceed the adult dose.</p>
          </list-item>
        </list>
        <p>If patients cannot take medication orally, antibiotics are administered through IV or intramuscular (IM) routes.</p>
        <list list-type="bullet">
          <list-item>
            <p>Ampicillin: 2 g of ampicillin is administered IV/IM for adults and 50 mg/kg for pediatric patients.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cefazolin or ceftriaxone: 1 g&#x000a0;of&#x000a0;cefazolin or ceftriaxone&#x000a0;is administered IV/IM for adults and 50 mg/kg for pediatric patients.</p>
          </list-item>
        </list>
        <p>Recent&#x000a0;AHA guidelines suggest that clindamycin is no longer recommended as an alternative antibiotic regimen for patients undergoing dental procedures due to the increased risk of severe adverse drug reactions associated with clindamycin.<xref ref-type="bibr" rid="article-29598.r5">[5]</xref><xref ref-type="bibr" rid="article-29598.r9">[9]</xref>&#x000a0;Usually, antibiotics&#x000a0;should be administered 30 to 60 minutes before the procedure. However, IV vancomycin must be administered&#x000a0;2 hours before the planned procedure. According to the 2013 guidelines for preoperative antimicrobial prophylaxis of infective endocarditis, the preferred timing for antibiotic administration is 60 minutes before surgery.<xref ref-type="bibr" rid="article-29598.r10">[10]</xref> In cases where antibiotic prophylaxis is inadvertently not administered&#x000a0;before the dental procedure, the drug can still be administered up to 2 hours after the procedure has been performed.<xref ref-type="bibr" rid="article-29598.r10">[10]</xref></p>
      </sec>
      <sec id="article-29598.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most frequently reported adverse drug reactions associated with amoxicillin include nausea, vomiting, and headache. Although severe adverse drug reactions, such as hives, angioedema, and anaphylaxis, are possible, their incidence is low.<xref ref-type="bibr" rid="article-29598.r11">[11]</xref> Conversely, fatal anaphylaxis resulting from a single dose of cephalosporin in patients with no history of allergy is estimated to be &#x0003c;1 per 1 million doses. Clindamycin may lead to more frequent and severe reactions, notably <italic toggle="yes">Clostridium difficile&#x02013;</italic>associated diarrhea, prompting recent AHA guidelines to no longer recommend its use.<xref ref-type="bibr" rid="article-29598.r5">[5]</xref>&#x000a0;</p>
        <p>Doxycycline is an alternative for patients intolerant&#x000a0;to penicillin, cephalosporin, or macrolide. Severe reactions from a single dose of doxycycline are infrequent.&#x000a0;However, a risk of cardiovascular events, especially torsades de pointes with ventricular tachycardia, is apparent from azithromycin use in patients with a prolonged QTc interval of &#x0003e;450&#x000a0;ms as detected by electrocardiogram (ECG). Therefore, caution should be exercised when prescribing azithromycin to patients with a prolonged QTc interval.<xref ref-type="bibr" rid="article-29598.r12">[12]</xref>&#x000a0;</p>
        <p>Clinicians should prescribe antibiotics for prophylaxis based on the patient's age, risk factors, comorbid conditions, and concurrent medications. Amoxicillin is contraindicated in individuals with a history of hypersensitivity or anaphylactic reactions to penicillin antibiotics. Doxycycline should not be used in pediatric patients or pregnant women. Macrolides are not recommended for patients with existing cardiac arrhythmias or those taking medications that can prolong the QTc interval. When administering doxycycline capsules or tablets, it is important to ensure that the patient consumes them with at least 240 mL (8 oz) of water. In addition, advise the patient to remain in an upright position for at least 30 minutes after ingesting the drug to reduce the risk of esophageal irritation and ulceration.</p>
        <p>When selecting antibiotics, it is crucial to consider the patient's medication regimen to prevent potential drug-drug interactions. A growing concern exists regarding the widespread use of antibiotics, which contributes to the emergence of resistant species, including the&#x000a0;<italic toggle="yes">S viridans</italic> group.<xref ref-type="bibr" rid="article-29598.r13">[13]</xref>&#x000a0;Therefore, antibiotics should be prescribed strictly according to indications, and healthcare facilities should implement antimicrobial stewardship programs to address and mitigate antibiotic resistance issues effectively.<xref ref-type="bibr" rid="article-29598.r5">[5]</xref></p>
      </sec>
      <sec id="article-29598.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Prophylaxis against infective endocarditis is not recommended in patients at risk of infective endocarditis undergoing non-dental procedures, including transesophageal echocardiogram, esophagogastroduodenoscopy, colonoscopy, or cystoscopy unless there is an active infection present. No recognized indication exists for prophylaxis during dental, gastrointestinal, or genitourinary procedures in patients with implantable cardiovascular devices. However, prophylaxis with an anti-staphylococcal antibiotic is warranted during cardiovascular device implantation and subsequent manipulation of the surgically created device pocket.<xref ref-type="bibr" rid="article-29598.r14">[14]</xref><xref ref-type="bibr" rid="article-29598.r15">[15]</xref></p>
        <p>For patients who have undergone coronary artery bypass graft surgery, antibiotic prophylaxis&#x000a0;is&#x000a0;unnecessary for dental procedures, as there is no increased risk of long-term infection. Similarly, antibiotic prophylaxis&#x000a0;is&#x000a0;not needed&#x000a0;for dental procedures for patients with coronary artery stents.<xref ref-type="bibr" rid="article-29598.r16">[16]</xref>&#x000a0;However, further studies are necessary to&#x000a0;evaluate&#x000a0;the efficacy of&#x000a0;antimicrobial prophylaxis in preventing infective endocarditis.<xref ref-type="bibr" rid="article-29598.r17">[17]</xref></p>
      </sec>
      <sec id="article-29598.s7" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Subacute infective endocarditis poses a grave threat if left untreated. Therefore, healthcare professionals, including physicians, mid-level practitioners, dentists, pharmacists, primary care providers, internists, and cardiologists, should stay abreast of the latest guidelines from the American College of Cardiology (ACA) and AHA regarding the prophylaxis of patients at risk for infective endocarditis.</p>
        <p>Prophylaxis against infective endocarditis is not recommended for patients at risk of the condition undergoing non-dental procedures such as transesophageal echocardiogram, esophagogastroduodenoscopy, colonoscopy, or cystoscopy unless there is an active infection present. In addition, antibiotic prophylaxis is unnecessary for dental procedures in patients who have undergone coronary artery bypass graft surgery, as there is no evidence of an increased risk of long-term infection. Similarly, antibiotic prophylaxis is not required for dental procedures in patients with coronary artery stents.<xref ref-type="bibr" rid="article-29598.r5">[5]</xref></p>
        <p>Prophylaxis against subacute bacterial endocarditis demands vigilant monitoring and effective communication among all members of the interprofessional healthcare team. Follow-up care necessitates seamless coordination among team members. This collaborative approach not only enhances patient outcomes but also optimizes treatment efficacy, aids in the prevention of antibiotic resistance, and reduces the occurrence of adverse drug reactions. Ultimately, it leads to an overall improvement in patient outcomes.&#x000a0;</p>
      </sec>
      <sec id="article-29598.s8">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29598&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29598">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29598/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29598">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-29598.s9">
        <title>References</title>
        <ref id="article-29598.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bor</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Woolhandler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nardin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brusch</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Himmelstein</surname>
                <given-names>DU</given-names>
              </name>
            </person-group>
            <article-title>Infective endocarditis in the U.S., 1998-2009: a nationwide study.</article-title>
            <source>PLoS One</source>
            <year>2013</year>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>e60033</fpage>
            <pub-id pub-id-type="pmid">23527296</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29598.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Habib</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lancellotti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Antunes</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bongiorni</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Casalta</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Del Zotti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dulgheru</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>El Khoury</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Erba</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Iung</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Miro</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Mulder</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Plonska-Gosciniak</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Roos-Hesselink</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Snygg-Martin</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Thuny</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tornos Mas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vilacosta</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Zamorano</surname>
                <given-names>JL</given-names>
              </name>
              <collab>ESC Scientific Document Group</collab>
            </person-group>
            <article-title>2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM).</article-title>
            <source>Eur Heart J</source>
            <year>2015</year>
            <month>Nov</month>
            <day>21</day>
            <volume>36</volume>
            <issue>44</issue>
            <fpage>3075</fpage>
            <page-range>3075-3128</page-range>
            <pub-id pub-id-type="pmid">26320109</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29598.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>HAMBURGER</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Acute and subacute bacterial endocarditis.</article-title>
            <source>Arch Intern Med</source>
            <year>1963</year>
            <month>Jul</month>
            <volume>112</volume>
            <fpage>1</fpage>
            <page-range>1-2</page-range>
            <pub-id pub-id-type="pmid">13952298</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29598.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dajani</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Taubert</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bolger</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Bayer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferrieri</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gewitz</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Shulman</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Nouri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Newburger</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Hutto</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pallasch</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Gage</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Levison</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Peter</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zuccaro</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Prevention of bacterial endocarditis: recommendations by the American Heart Association.</article-title>
            <source>J Am Dent Assoc</source>
            <year>1997</year>
            <month>Aug</month>
            <volume>128</volume>
            <issue>8</issue>
            <fpage>1142</fpage>
            <page-range>1142-51</page-range>
            <pub-id pub-id-type="pmid">9260427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29598.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilson</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Gewitz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lockhart</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Bolger</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>DeSimone</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Kazi</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Couper</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Beaton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kilmartin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Miro</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Sable</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Baddour</surname>
                <given-names>LM</given-names>
              </name>
              <collab>American Heart Association Young Hearts Rheumatic Fever, Endocarditis and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; and the Council on Quality of Care and Outcomes Research</collab>
            </person-group>
            <article-title>Prevention of Viridans Group Streptococcal Infective Endocarditis: A Scientific Statement From the American Heart Association.</article-title>
            <source>Circulation</source>
            <year>2021</year>
            <month>May</month>
            <day>18</day>
            <volume>143</volume>
            <issue>20</issue>
            <fpage>e963</fpage>
            <page-range>e963-e978</page-range>
            <pub-id pub-id-type="pmid">33853363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29598.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Otto</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Nishimura</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Bonow</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Carabello</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Erwin</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Gentile</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jneid</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Krieger</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Mack</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McLeod</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>O'Gara</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Rigolin</surname>
                <given-names>VH</given-names>
              </name>
              <name>
                <surname>Sundt</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Toly</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2021</year>
            <month>Feb</month>
            <day>02</day>
            <volume>143</volume>
            <issue>5</issue>
            <fpage>e72</fpage>
            <page-range>e72-e227</page-range>
            <pub-id pub-id-type="pmid">33332150</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29598.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loyola-Rodriguez</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Franco-Miranda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Loyola-Leyva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Perez-Elizalde</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Contreras-Palma</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sanchez-Adame</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Prevention of infective endocarditis and bacterial resistance to antibiotics: A brief review.</article-title>
            <source>Spec Care Dentist</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>39</volume>
            <issue>6</issue>
            <fpage>603</fpage>
            <page-range>603-609</page-range>
            <pub-id pub-id-type="pmid">31464005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29598.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verhagen</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Vedder</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Speelman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>van der Meer</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Antimicrobial treatment of infective endocarditis caused by viridans streptococci highly susceptible to penicillin: historic overview and future considerations.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2006</year>
            <month>May</month>
            <volume>57</volume>
            <issue>5</issue>
            <fpage>819</fpage>
            <page-range>819-24</page-range>
            <pub-id pub-id-type="pmid">16549513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29598.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Khanafer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Daneman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fisman</surname>
                <given-names>DN</given-names>
              </name>
            </person-group>
            <article-title>Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2013</year>
            <month>May</month>
            <volume>57</volume>
            <issue>5</issue>
            <fpage>2326</fpage>
            <page-range>2326-32</page-range>
            <pub-id pub-id-type="pmid">23478961</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29598.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bratzler</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Dellinger</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Perl</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Auwaerter</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Bolon</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Fish</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Napolitano</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Sawyer</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Slain</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Weinstein</surname>
                <given-names>RA</given-names>
              </name>
              <collab>American Society of Health-System Pharmacists (ASHP)</collab>
              <collab>Infectious Diseases Society of America (IDSA)</collab>
              <collab>Surgical Infection Society (SIS)</collab>
              <collab>Society for Healthcare Epidemiology of America (SHEA)</collab>
            </person-group>
            <article-title>Clinical practice guidelines for antimicrobial prophylaxis in surgery.</article-title>
            <source>Surg Infect (Larchmt)</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>73</fpage>
            <page-range>73-156</page-range>
            <pub-id pub-id-type="pmid">23461695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29598.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thornhill</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Dayer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Durkin</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Lockhart</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Baddour</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Risk of Adverse Reactions to Oral Antibiotics Prescribed by Dentists.</article-title>
            <source>J Dent Res</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>98</volume>
            <issue>10</issue>
            <fpage>1081</fpage>
            <page-range>1081-1087</page-range>
            <pub-id pub-id-type="pmid">31314998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29598.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chai</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bai</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The cardiotoxicity of macrolides: a systematic review.</article-title>
            <source>Pharmazie</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>65</volume>
            <issue>9</issue>
            <fpage>631</fpage>
            <page-range>631-40</page-range>
            <pub-id pub-id-type="pmid">21038838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29598.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Poggensee</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Suda</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Bulman</surname>
                <given-names>ZP</given-names>
              </name>
            </person-group>
            <article-title>Antibiotic susceptibility patterns of viridans group streptococci isolates in the United States from 2010 to 2020.</article-title>
            <source>JAC Antimicrob Resist</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>dlac049</fpage>
            <pub-id pub-id-type="pmid">35599725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29598.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weddell</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Current guidelines and dental applications for the SBE prophylaxis.</article-title>
            <source>J Indiana Dent Assoc</source>
            <year>1987</year>
            <season>May-Jun</season>
            <volume>66</volume>
            <issue>3</issue>
            <fpage>7</fpage>
            <page-range>7-9</page-range>
            <pub-id pub-id-type="pmid">2957474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29598.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thornhill</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Dayer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Forde</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Corey</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>VH</given-names>
              </name>
              <name>
                <surname>Couper</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Lockhart</surname>
                <given-names>PB</given-names>
              </name>
            </person-group>
            <article-title>Impact of the NICE guideline recommending cessation of antibiotic prophylaxis for prevention of infective endocarditis: before and after study.</article-title>
            <source>BMJ</source>
            <year>2011</year>
            <month>May</month>
            <day>03</day>
            <volume>342</volume>
            <fpage>d2392</fpage>
            <pub-id pub-id-type="pmid">21540258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29598.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>S&#x000e0;ndor</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Carmichael</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Vasilakos</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Revised American Heart Association guidelines for the prevention of bacterial endocarditis: highlights of specific changes for the dental profession.</article-title>
            <source>J Can Dent Assoc</source>
            <year>1998</year>
            <month>Feb</month>
            <volume>64</volume>
            <issue>2</issue>
            <fpage>114</fpage>
            <page-range>114-7</page-range>
            <pub-id pub-id-type="pmid">9509818</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29598.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anupama</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gopalakrishnan</surname>
                <given-names>NS</given-names>
              </name>
            </person-group>
            <article-title>Infective endocarditis, the conundrum of antibiotic prophylaxis.</article-title>
            <source>Indian J Dent Res</source>
            <year>1995</year>
            <season>Jul-Sep</season>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>83</fpage>
            <page-range>83-93</page-range>
            <pub-id pub-id-type="pmid">9495112</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
